Cutaneous Squamous Cell Carcinoma – US market revenue will increase by double fold by 2025

The estimated total number of incident cases of Cutaneous Squamous Cell Carcinoma (cSCC) in the US is expected to reach 713,294 by 2025 as per the latest report of DelveInsight. Non-melanoma skin cancer is the most common skin cancer in the United States. It is broadly classified into Basal cell carcinoma (BCC) and Squamous cell carcinoma (SCC). Basal cell carcinoma accounts for 75-80% of non-melanoma cancers and Squamous cell carcinoma accounts for about 20% of non- melanoma cancers. Remaining 5% of non-melanoma cancer includes- actinic keratosis, etc. The cSCC market is expected to see a growth at a CAGR of 5.5% in the 7MM.

According to “Cutaneous Squamous Cell Carcinoma (cSCC) - Market Insights, Epidemiology and Market Forecast-2025”, US has the maximum market share in the 7MM market of Cutaneous Squamous Cell Carcinoma due to the maximum number of recorded cSCC incident cases. With more than 60% of the total market share US will see a steady growth in the upcoming future. Spain has the minimum number of incident cases and minimum market share of about 3.1% among the 7MM. The market revenue of US was more than the rest 6MM collective revenue and the US market revenue will increase by 2 folds by 2025 as compared to that in 2016. There are various off-label drugs available for the treatment of the given indication but no approved drugs are available in the market yet.

There are various treatments available for the treatment of cSCC. Several guidelines have been published for the treatment as per the patient diagnosis and other factors. Electrodessication and curettage is a simple technique that can be used to treat localized, superficial cSCC, while surgical excision and Mohs micrographic surgery are the two primary treatment options for invasive cSCC. Radiation therapy is typically used as an adjuvant to surgery, with primary radiation therapy typically reserved for patients who are unable to undergo surgical excision. Chemotherapy may be considered as adjuvant therapy in select highest-risk cases of cSCC. Some marketed drugs are Fluorouracil, Xeloda, Cisplatin and many others but no approved drugs available yet.

The latest report has covered complete information about the cSCC including region-wise incident cases with special emphasize on the 7MM. Country-wise market analysis to identify the regions which will provide maximum market growth. Complete treatment algorithm is provided with marketed drugs profiling covering all the details to understand drug specific details. All the unmet needs are captured to identify the areas of improvement in the field of cSCC. All these information provides in-depth insight into the cSCC market which helps in identifying the possible market movers and barriers to maximize the market share and frame the planning strategies accordingly.

Reasons to buy:

• The report will help in developing business strategies by understanding trends shaping and driving the cSCC market.

• To understand the future market competition in the cSCC market and Insight reviews of the key market drivers and barriers.

• Organize sales and marketing efforts by identifying the best opportunities for cSCC in the US, Europe (Germany, Spain, Italy, France and the United Kingdom) and Japan.

• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.

• To understand the expected market scenario of the upcoming therapies in the market.

Table of Content:
Report Introduction
Table of Contents
Market Overview at a Glance
Total Market Share Distribution of Cutaneous Squamous Cell Carcinoma for 7MM in 2016
Total Market Share Distribution of Cutaneous Squamous Cell Carcinoma for 7MM in 2025
Introduction
Signs and Symptoms
Pathophysiology
Sub-types of cSCC
Risk Factors
Staging of cSCC
Diagnosis
Epidemiology and Patient Population
Total number of Incident cases – Region Wise – (2016 & 2025)
Total number of Incident cases – 7MM Countries – (2016 & 2025)
United States
Germany
France
United Kingdom
Spain
Italy
Japan
Treatment Algorithm
United States
NCCN Guidelines
Europe
British Association of dermatology (BAD) Guidelines
French Dermatology Recommendations Association (aRED)
European Dermatology Forum London Cancer Skin Pathway Board
National Cancer Institute
Unmet Needs
Marketed Drugs
5-Fluorouracil (5-FU)
MOA
Study
Xeloda
MOA
Study
Cisplatin
MOA
Study
Bleomycin
MOA
Study
Doxorubicin
MOA
Cetuximab
MOA
Study
Gefitinib
MOA
Study
Cutaneous Squamous Cell Carcinoma (cSCC): Country-Wise Market Analysis
7 Major Market Size of Cutaneous Squamous Cell Carcinoma (cSCC) (2015-2025)
Region-Specific Market Distribution and Comparison
Overview on Cutaneous Squamous Cell Carcinoma (cSCC) (2016)
Overview on Cutaneous Squamous Cell Carcinoma (cSCC) (2025)
Global Cutaneous Squamous Cell Carcinoma (cSCC): Market Analysis
United States Market Size
Europe Market Outlook
Germany Market Size
France Market Size
United Kingdom Market Size
Spain Market Size
Italy Market Size
Japan Market Size
Market Drivers
Market Barriers
Appendix

For more details please visit: http://bit.ly/2gMOCJP

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. We support companies by providing end to end comprehensive solutions to improve their performance and in making a long lasting decision for their businesses.

We advise leading decision makers on their critical issues and opportunities; Research & Development, Strategy Making, Commercial, Operations, Competitive Intelligence, Competitive Landscaping and Mergers & Acquisition across all the Pharma and Biotech industries and geographies. We serve our clients by delivering practical and enduring results and equipping our clients to grow and lead.

Tel: +91-11-4568 9769 | +91 9650213330
Email: info@delveinsight.com
DelveInsight
New Delhi

This release was published on openPR.